Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionProShare Advisors LLC
Latest Disclosed Ownership174,013 shares
Latest Disclosed Value $ 57,575,682
ProShare Advisors LLC reports 17.56% decrease in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On April 24, 2026 - ProShare Advisors LLC filed a 13F-HR form disclosing ownership of 174,013 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $49,715,514 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 6, 2026 disclosing 211,077 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of -17.56% during the quarter. The current value of the position is $45,330,386 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-24 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 174,013 -37,064 -17.56 57,576 -31.40 0.0853
2026-02-06 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 211,077 206,446 4,457.91 83,935 3,876.03 0.1481
2025-11-06 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,631 390 9.20 2,112 52.75 0.0044
2025-08-07 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,241 -1,599 -27.38 1,383 -12.31 0.0028
2025-05-08 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,840 -270 -4.42 1,577 9.67 0.0036
2025-02-14 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,110 -1,476 -19.46 1,438 -31.11 0.0033
2024-11-14 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7,586 -223 -2.86 2,086 9.96 0.0051
2024-08-13 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7,809 -1,018 -11.53 1,898 43.82 0.0051
2024-05-08 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,827 809 10.09 1,319 -14.02 0.0035
2024-02-14 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,018 -154 -1.88 1,535 6.01 0.0047
2023-11-13 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,172 115 1.43 1,447 -5.42 0.0045
2023-08-10 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,057 -757 -8.59 1,530 -13.31 0.0044
2023-05-26 2023-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 8,814 -3,227 -26.80 1,766 -38.31 0.0054
2023-05-12 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,814 -3,227 1,766 0.0056
2023-02-02 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,041 33 0.27 2,862 19.01 0.0100
2022-11-07 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,008 619 5.44 2,404 44.73 0.0092
2022-08-01 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,389 -3,801 -25.02 1,661 -33.05 0.0055
2022-05-10 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 15,190 -4,656 -23.46 2,481 -26.27 0.0053
2022-02-08 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 19,846 -8,361 -29.64 3,365 -36.82 0.0066
2021-11-12 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 28,207 2,838 11.19 5,326 23.83 0.0150
2021-08-13 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 25,369 6,983 37.98 4,301 65.68 0.0126
2021-05-14 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 18,386 -1,631 -8.15 2,596 -0.23 0.0082
2021-02-09 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 20,017 -677 -3.27 2,602 -13.64 0.0097
2020-11-13 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 20,694 522 2.59 3,013 0.84 0.0139
2020-08-03 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 20,172 2,783 16.00 2,988 57.84 0.0160
2020-05-15 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 17,389 -9,386 -35.06 1,893 -38.62 0.0136
2020-02-12 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 26,775 -5,944 -18.17 3,084 17.22 0.0143
2019-11-12 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 32,719 -677 -2.03 2,631 8.58 0.0147
2019-08-13 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 33,396 -6,523 -16.34 2,423 -35.04 0.0145
2019-05-15 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 39,919 3,032 8.22 3,730 38.71 0.0223
2019-02-14 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 36,887 -7,327 -16.57 2,689 -30.52 0.0188
2018-11-14 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 44,214 -19 -0.04 3,870 -11.18 0.0263
2018-08-13 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 44,233 -4,032 -8.35 4,357 -24.20 0.0292
2018-05-14 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 48,265 -7,365 -13.24 5,748 -18.68 0.0374
2018-02-14 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 55,630 2,152 4.02 7,068 12.49 0.0490
2017-11-13 2017-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 53,478 4,973 10.25 6,283 62.39 0.0577
2017-08-11 2017-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 48,505 1,078 2.27 3,869 59.15 0.0385
2017-05-12 2017-03-31 13F/A-2 ALNYLAM PHARMACEUTICALS COM 02043Q107 47,427 -10,286 -17.82 2,431 12.49 0.0254
2017-05-08 2017-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 47,427 0 2,431 0.0254
2017-04-25 2017-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 47,427 2,431
2017-02-13 2016-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 57,713 1,507 2.68 2,161 -43.28 0.0239
2016-11-10 2016-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 56,206 -9,945 -15.03 3,810 3.79 0.0532
2016-08-12 2016-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 66,151 1,528 2.36 3,671 -9.49 0.0473
2016-05-06 2016-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 64,623 -6,281 -8.86 4,056 -39.24 0.0558
2016-02-05 2015-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 70,904 3,682 5.48 6,675 23.57 0.0809
2015-11-06 2015-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 67,222 -4,118 -5.77 5,402 -36.83 0.0759
2015-08-11 2015-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 71,340 71 0.10 8,552 14.92 0.1183
2015-05-08 2015-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 71,269 71,269 0.00 7,442 0.0877
2015-01-30 2014-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -41,789 -100.00 0 -100.00
2014-11-06 2014-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 41,789 -6,904 -14.18 3,264 6.11 0.0433
2014-08-08 2014-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 48,693 -61,005 -55.61 3,076 -58.23 0.0399
2014-05-07 2014-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 109,698 75,834 223.94 7,365 238.15 0.0921
2014-02-04 2013-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 33,864 -26,359 -43.77 2,178 -43.50 0.0325
2013-11-07 2013-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 60,223 12,552 26.33 3,855 160.83 0.0915
2013-07-25 2013-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 47,671 47,671 1,478 0.0290
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.